Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 4/20 | 0.44 |
| ▸ | NPY1R | P25929 | 2/20 | 0.44 |
| ▸ | KLK7 | P49862 | 2/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21096611 | 1.00 | NPY4R (0.44) | NPY4RNPY1RKLK7KLK5OPRM1 | |
| SCHEMBL26624541 | 0.98 | KLK7 (0.47) | NPY4RNPY1RKLK7KLK5MAPT | |
| SCHEMBL19862064 | 0.95 | CTSS (0.43) | KLK7KLK5MAPTPOLBMAPK1 | |
| SCHEMBL30241791 | 0.90 | MAPT (0.49) | KLK7KLK5MAPTPOLBMAPK1 | |
| SCHEMBL18072614 | 0.88 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL21062366 | 0.88 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL19862400 | 0.88 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL21062302 | 0.88 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL19862399 | 0.88 | NPY4R (0.52) | NPY4RNPY1ROPRM1RENNPY2R | |
| SCHEMBL19862397 | 0.88 | NPY4R (0.52) | NPY4RNPY1ROPRM1RENNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725506-A2 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-3986401-B1 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | STEALTH BIOTHERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250009717-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, PARKINSON’S DISEASE, PARKINSON’S DISEASE WITH DEMENTIA, DEMENTIA WITH LEWY BODIES, AND MULTIPLE SYSTEM ATROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-01-09 | — | — | US | disclosed |
| EP-4419123-A1 | METHODS AND COMPOSITIONS COMPRISING PEPTIDOMIMITICS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS | Stealth BioTherapeutics Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12016843-B2 | Compositions and methods for the treatment of amyotrophic lateral sclerosis, parkinson's disease, parkinson's disease with dementia, dementia with lewy bodies, and multiple system atrophy | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240059734-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230405080-A1 | METHODS AND COMPOSITIONS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-12-21 | — | — | US | disclosed |
| US-11795196-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4218785-A2 | MITOCHONDRIA-TARGETING PEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11273149-B2 | Compositions and methods for the treatment of amyotrophic lateral sclerosis, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, and multiple system atrophy | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-11273149-B2 | Compositions and methods for the treatment of amyotrophic lateral sclerosis, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, and multiple system atrophy | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3800192-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | Stealth Biotherapeutics Corp (MC) | 2021-04-07 | — | — | EP | disclosed |
| US-20210023062-A1 | Compositions and Methods for the Treatment of Amyotrophic Lateral Sclerosis, Parkinson's Disease, Parkinson's Disease with Dementia, Dementia with Lewy Bodies, and Multiple System Atrophy | STEALTH BIOTHERAPEUTICS INC. | 2021-01-28 | — | — | US | disclosed |
| WO-2021016462-A1 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-I-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | STEALTH BIOTHERAPEUTICS CORP (MC) | 2021-01-28 | — | — | WO | disclosed |
| EP-3265109-B1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | STEALTH BIOTHERAPEUTICS CORP (MC) | 2020-10-21 | — | — | EP | disclosed |
| US-20200308221-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | STEALTH BIOTHERAPEUTICS CORP (MC) | 2020-10-01 | — | — | US | disclosed |
| US-10633415-B2 | Processes for preparing pharmaceutically relevant peptides | STEALTH BIOTHERAPEUTICS CORP (MC) | 2020-04-28 | — | — | US | disclosed |
| WO-2019118878-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS CORP. (MC) | 2019-06-20 | — | — | WO | disclosed |
| US-20180044378-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044378-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | ADM2, VIP, PEPD | NPY4R 135/4885NPY1R 140/4885KLK7 359/4885 |
| US-10633415-B2 | Processes for preparing pharmaceutically relevant peptides | ADM2, VIP, PEPD | NPY4R 135/4885NPY1R 140/4885KLK7 359/4885 |
| US-20230405080-A1 | METHODS AND COMPOSITIONS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS | UACA, EYA3, ALDH1A2 | NPY4R 1579/4885NPY1R 787/4885KLK7 2594/4885 |
| US-20200308221-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | ADM2, VIP, PEPD | NPY4R 135/4885NPY1R 140/4885KLK7 359/4885 |
| US-11795196-B2 | Mitochondria-targeting peptides | HSPE1, TFAM, TNNI3 | NPY4R 2936/4885NPY1R 2552/4885KLK7 4079/4885 |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | ADM2, VIP, PEPD | NPY4R 135/4885NPY1R 140/4885KLK7 359/4885 |
| US-11273149-B2 | Compositions and methods for the treatment of amyotrophic lateral sclerosis, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, and multiple system atrophy | NLN, TARDBP, PARK7 | NPY4R 2566/4885NPY1R 2391/4885KLK7 4171/4885 |
| US-20210023062-A1 | Compositions and Methods for the Treatment of Amyotrophic Lateral Sclerosis, Parkinson's Disease, Parkinson's Disease with Dementia, Dementia with Lewy Bodies, and Multiple System Atrophy | NLN, TARDBP, PARK7 | NPY4R 2566/4885NPY1R 2391/4885KLK7 4171/4885 |
| US-12016843-B2 | Compositions and methods for the treatment of amyotrophic lateral sclerosis, parkinson's disease, parkinson's disease with dementia, dementia with lewy bodies, and multiple system atrophy | NLN, TARDBP, PARK7 | NPY4R 2566/4885NPY1R 2391/4885KLK7 4171/4885 |
| US-20240059734-A1 | MITOCHONDRIA-TARGETING PEPTIDES | HSPE1, TFAM, TNNI3 | NPY4R 2936/4885NPY1R 2552/4885KLK7 4079/4885 |
| US-20250009717-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, PARKINSON’S DISEASE, PARKINSON’S DISEASE WITH DEMENTIA, DEMENTIA WITH LEWY BODIES, AND MULTIPLE SYSTEM ATROPHY | TARDBP, NLN, PARK7 | NPY4R 2504/4885NPY1R 2413/4885KLK7 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.